A phase 3 trial of Cogent Biosciences’ bezuclastinib has hit its primary endpoint, teeing the biotech up to seek FDA approval ...

To make matters worse, the biotech realized that the same duff drug product had been used in a separate ongoing study of ...

Apogee Therapeutics’ anti-IL-13 antibody has been tied to a 71% reduction in eczema severity after 16 weeks, hitting the main ...

Chugai, a Japanese company majority owned by Roche, has identified Gero’s platform as complementary to its own capabilities.

In the July 2 release, 4DMT explained that the 25% layoffs are part of a move to “streamline operations to offset additional ...

On Wednesday, Biokin reported (PDF) positive topline results from a phase 3 trial of the ADC. The study enrolled patients ...

Catalio Capital Management has closed its fourth venture fund with more than $400 million that will be used in part to launch ...

AbbVie is on board with the idea. The Big Pharma will pay up to $2.1 billion in cash at closing to acquire Capstan. In return ...

Storied Japanese pharma Shionogi is upping its arsenal in the fight against antibiotic resistance. | Storied Japanese pharma ...

Amgen’s investigational monoclonal antibody paired with chemotherapy significantly improved overall survival for patients in ...

Vyne Therapeutics has given up hopes of resuming a plaque psoriasis trial for its BET inhibitor placed on hold by the FDA, ...

After claiming an FDA approval last year, Intuitive has obtained a greenlight in Europe for its latest surgical robot, the da ...